On August 8, 2023 shares of BIOLASE, Inc. (NASDAQ: BIOL), soar 27% as the medical device company inks quite a significant agreement. They entered into a partnership with the Department of Defense to spearhead the production of cutting-edge dental equipment and supplies. A key highlight of this collaboration is the Biolase Waterlase Express Endodontic Laser, which takes center stage. While the financial intricacies of the contract remain confidential, this development underscores a substantial advancement for Biolase.

About Waterlase Dentistry:
Turning our attention to the Waterlase Express, envision a state-of-the-art laser designed to simplify the work of dentists. It boasts an intuitive tablet interface and sophisticated clinical animations, designed to streamline dental procedures. Furthermore, it guides practitioners through meticulous protocols for managing a spectrum of dental applications, including perio, peri-implantitis, and other restorative treatments.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
What sets the Waterlase Express apart is its accessibility; it’s both cost-effective and portable. This dual feature empowers a wider demographic to benefit from laser dentistry, marking a notable leap forward in the field.
In alignment with their unwavering commitment to excellence, Biolase has inaugurated a state-of-the-art training facility. This establishment is dedicated to imparting comprehensive courses on leveraging the Waterlase all-tissue laser across diverse dental disciplines, encompassing restorative dentistry, periodontics, endodontics, and more.
Biolase’s domain expertise encompasses the entire spectrum of dental lasers and related products. From development and manufacturing to marketing and sales, they remain at the forefront of dental technology innovation, with a resolute focus on elevating patient care standards and enhancing outcomes within the dental realm.
BIOL Stock Statistics:
https://twitter.com/IncredibleTrade/status/1688998533465042944?s=20
More significantly, the company has recently undergone a 1-for-100 reverse stock split, effectively reducing the available outstanding shares from 104 million to 1.04 million. According to data from YahooFinance, the float now stands at a mere 271.52 thousand shares – a notably low figure, especially within the context of companies trading on the NASDAQ. As highlighted in previous articles, stocks with tightly held floats under 10 million shares are commonly associated with swift movements, inducing a substantial degree of volatility. While these types of stocks have the potential to yield gains exceeding 100% overnight, it’s imperative to exercise caution, as they can also carry the risk of wiping out investments entirely.
https://twitter.com/stockballa/status/1688930765227294720?s=20
It is also worth noting data sourced from CNN Money, BIOL has garnered insights from four analysts regarding its anticipated price trajectory over the next 12 months. The median target price is projected at $35.00, with an optimistic estimate reaching as high as $1,000.00 and a conservative estimation at $10.00. These figures imply a potential surge of approximately 493.22% from the recent recorded price of $5.90, presenting an intriguing outlook for the company’s future valuation.
We will update you on BIOL when more details emerge, subscribe to Microcapdaily to follow along!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Picture by geralt from Pixabay